Liquidia Dirección

Dirección controles de criterios 3/4

El CEO de Liquidia es Roger Jeffs , nombrado en Jan 2022, tiene una permanencia de 2.83 años. compensación anual total es $4.89M, compuesta por 14.1% salario y 85.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.38% de las acciones de la empresa, por valor de $20.49M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 5.1 años, respectivamente.

Información clave

Roger Jeffs

Chief Executive Officer (CEO)

US$4.9m

Compensación total

Porcentaje del salario del CEO	14.1%
Permanencia del CEO	2.8yrs
Participación del CEO	2.4%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	5.1yrs

Actualizaciones recientes de la dirección

Recent updates

Is Liquidia (NASDAQ:LQDA) A Risky Investment?

Jul 18

Broker Revenue Forecasts For Liquidia Corporation (NASDAQ:LQDA) Are Surging Higher

Jan 19

Liquidia Corporation's (NASDAQ:LQDA) P/S Still Appears To Be Reasonable

Dec 20

Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?

Aug 17

Need To Know: Analysts Are Much More Bullish On Liquidia Corporation (NASDAQ:LQDA) Revenues

Mar 18

Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?

Feb 06

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Roger Jeffs en comparación con los beneficios de Liquidia?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$119m
Jun 30 2024	n/a	n/a	-US$112m
Mar 31 2024	n/a	n/a	-US$108m
Dec 31 2023	US$5m	US$689k	-US$79m
Sep 30 2023	n/a	n/a	-US$58m
Jun 30 2023	n/a	n/a	-US$51m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$11m	US$325k	-US$41m
Sep 30 2022	n/a	n/a	-US$46m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$41m
Dec 31 2021	US$93k	n/a	-US$35m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$54m
Dec 31 2020	US$89k	n/a	-US$60m

Compensación vs. Mercado: La compensación total de Roger($USD4.89M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.21M).

Compensación vs. Ingresos: La compensación de Roger ha sido consistente con los resultados de la empresa en el último año.

CEO

Roger Jeffs (62 yo)

2.8yrs

Permanencia

US$4,889,498

Compensación

Dr. Roger A. Jeffs, Ph D., serves as Director at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since November 2020 and serves as its Chief Executive Officer from January 3, 2022. He...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Roger Jeffs	CEO & Director	2.8yrs	US$4.89m	2.38% $ 20.5m
Michael Kaseta	COO & CFO	4yrs	US$2.43m	0.12% $ 992.7k
Russell Schundler	General Counsel & Corporate Secretary	3.7yrs	US$2.06m	0.39% $ 3.4m
William Kenan	Co-Founder	20.8yrs	sin datos	sin datos
Ginger Denison	Co-Founder	20.8yrs	sin datos	sin datos
Sarah Krepp	Vice President of People & Culture	1.4yrs	sin datos	sin datos
Jason Adair	Chief Business Officer	1.3yrs	sin datos	0.072% $ 623.2k
Scott Moomaw	Chief Commercial Officer	4yrs	sin datos	0.066% $ 571.0k
Rajeev Saggar	Chief Medical Officer	2.3yrs	sin datos	0.099% $ 852.4k
Michael Hunter	Senior Vice President of Manufacturing Operations	less than a year	sin datos	sin datos

3.3yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LQDA se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Roger Jeffs	CEO & Director	4yrs	US$4.89m	2.38% $ 20.5m
Arthur Kirsch	Independent Director	8.2yrs	US$186.91k	0.038% $ 325.1k
Joanna Horobin	Independent Director	5.2yrs	US$176.91k	0% $ 0
Burton Goldstein	Board Observer	no data	sin datos	sin datos
Michael Raab	Board Observer	no data	sin datos	sin datos
Martin Lagod	Board Observer	no data	sin datos	sin datos
Stephen Bloch	Independent Chairman	15.3yrs	US$211.91k	0% $ 0
Paul Manning	Independent Director	4.8yrs	US$170.66k	7.26% $ 62.4m
David Johnson	Independent Director	3.6yrs	US$174.41k	0% $ 0
Damian deGoa	Director	3.9yrs	US$166.91k	0.056% $ 484.8k
Ramandeep Singh	Independent Director	6.8yrs	US$178.16k	0% $ 0
Katherine Rielly-Gauvin	Independent Director	5.1yrs	US$175.66k	0% $ 0

5.1yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de LQDA se considera experimentada (5.1 años de antigüedad promedio).

Liquidia Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Liquidia Corporation, Annual General Meeting, Jun 20, 2024

CEO & Director recently sold US$452k worth of stock

Liquidia Corporation Announces Updates to Operations Leadership

Insufficient new directors

Independent Director recently bought US$2.0m worth of stock

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Profitability

Liquidia Corporation to Report Q3, 2024 Results on Nov 13, 2024

Liquidia Corporation to Report Q3, 2024 Results on Nov 11, 2024

Liquidia Corporation Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million.

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million.

Liquidia Corporation Files Litigation to Challenge Regulatory Exclusivity Blocking Access to Yutrepia (Treprostinil) Inhalation Powder for Patients Suffering with PAH and PH-ILD

Consensus revenue estimates decrease by 49%, EPS upgraded

No longer forecast to breakeven

New minor risk - Share price stability

Price target decreased by 7.1% to US$25.71

Liquidia Corporation Announces U.S. Food and Drug Administration Grants Tentative Approval of YUTPIA®? (Treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Consensus revenue estimates fall by 45%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

Liquidia Corporation to Report Q2, 2024 Results on Aug 07, 2024

Is Liquidia (NASDAQ:LQDA) A Risky Investment?

Price target increased by 10% to US$27.67

No longer forecast to breakeven

District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch

Consensus revenue estimates increase by 18%, EPS downgraded

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

No longer forecast to breakeven

Liquidia Corporation to Report Q1, 2024 Results on May 14, 2024

Liquidia Corporation, Annual General Meeting, Jun 20, 2024

Liquidia Corporation Provides Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA Approval of YUTREPIA™ (treprostinil) Inhalation Powder

CEO & Director recently sold US$452k worth of stock

Consensus EPS estimates fall by 15%, revenue upgraded

Price target increased by 29% to US$27.33

Full year 2023 earnings: EPS and revenues miss analyst expectations

Liquidia Corporation to Report Fiscal Year 2023 Results on Mar 13, 2024

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (Treprostinil) Inhalation Powder

Liquidia Corporation Announces the Launch of Yutrepiatm (Treprostinil) Inhalation Powder

Broker Revenue Forecasts For Liquidia Corporation (NASDAQ:LQDA) Are Surging Higher

Liquidia Corporation Announces Updates to Operations Leadership

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Liquidia Corporation Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Legend Aggregator, LP

Insufficient new directors

Forecast to breakeven in 2026

Price target increased by 31% to US$18.29

Independent Director recently bought US$2.0m worth of stock

Liquidia Corporation's (NASDAQ:LQDA) P/S Still Appears To Be Reasonable

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $24.999999 million.

New minor risk - Shareholder dilution

Liquidia Corporation has filed a Follow-on Equity Offering in the amount of $24.999999 million.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Liquidia Corporation to Report Q3, 2023 Results on Nov 07, 2023

FDA Accepts Liquidia Corporation's Submission to Add PH-ILD to YUTREPIA™ Label

United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office

Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?

Consensus EPS estimates fall by 34%, revenue upgraded

New minor risk - Profitability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Liquidia Corporation to Report Q2, 2023 Results on Aug 10, 2023

Liquidia Corporation Submits Amendment to Add Ph-Ild Indication to Tentatively Approved Nda for Yutpia (Treprostinil) Inhalation Powder

Liquidia Corporation Announces U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation

Price target increased by 15% to US$16.17

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.30 loss in 1Q 2022)

Need To Know: Analysts Are Much More Bullish On Liquidia Corporation (NASDAQ:LQDA) Revenues

No longer forecast to breakeven

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?

Forecast to breakeven in 2025

Price target increased to US$14.83